Skip to main content
Quest Diagnostics

Impact of the COVID-19 Pandemic on Chlamydia and Gonorrhea Screening in the US

Impact of the COVID-19 Pandemic on Chlamydia and Gonorrhea Screening in the US

Authors: Pinto CN, Niles JK, Kaufman HW, Marlowe EM, Alagia D, Chi G, Van Der Pol B

Citation: Am J Prev Med. 2021 May 18;S0749-3797(21)00217-8. doi: 10.1016/j.amepre.2021.03.009. Online ahead of print.

Specialties: Infectious Disease, COVID-19,, Women's Health/OB/GYN

Download key summary

Related content

Publication
Chlamydia and Gonorrhea Shifting Age Based Positivity Among Young Females 2010 2017
Conference Presentation
STI Testing Beyond Chlamydia trachomatis Neisseria gonorrhea Mycoplasma genitalium Trichomonas vaginalis Trends Data From a US Commercial Laboratory
Test FAQ
Chlamydia trachomatis Neisseria gonorrhoeae RNA TMA

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.